2927-97-1

Upstream product

• 98-16-8 3-trifluoromethylaniline 
• 98-74-8 4-Nitrobenzenesulfonyl chloride 

Downstream Products

• 339-40-2 4-amino-N-[3-(trifluoromethyl)phenyl]benzene-1-sulfonamide 
• 898217-34-0 N-cyclohexyl-4-oxo-6-(N-(3-(trifluoromethyl)phenyl)sulfamoyl)-1,4-dihydroquinoline-3-carboxamide 
• 898191-84-9 4-oxo-N-(pyridin-3-ylmethyl)-6-(N-(3-(trifluoromethyl)phenyl)sulfamoyl)-1,4-dihydroquinoline-3-carboxamide 
• 1449221-46-8 N-(furan-2-ylmethyl)-4-oxo-6-(N-(3-(trifluoromethyl)phenyl)sulfamoyl)-1,4-dihydroquinoline-3-carboxamide 
• 1449221-44-6 N-(3-methoxybenzyl)-4-oxo-6-(N-(3-(trifluoromethyl)phenyl)sulfamoyl)-1,4-dihydroquinoline-3-carboxamide 
• 1449221-42-4 N-(4-methoxybenzyl)-4-oxo-6-(N-(3-(trifluoromethyl)phenyl)sulfamoyl)-1,4-dihydroquinoline-3-carboxamide 
• 1449221-41-3 N-(3-fluorobenzyl)-4-oxo-6-(N-(3-(trifluoromethyl)phenyl)sulfamoyl)-1,4-dihydroquinoline-3-carboxamide 
• 1449221-40-2 N-(4-fluorobenzyl)-4-oxo-6-(N-(3-(trifluoromethyl)phenyl)sulfamoyl)-1,4-dihydroquinoline-3-carboxamide 
• 388621-83-8 4-oxo-6-(N-(3-(trifluoromethyl)phenyl)sulfamoyl)-1,4-dihydroquinoline-3-carboxylic acid 
• 1449221-74-2 ethyl 4-oxo-6-(N-(3-(trifluoromethyl)phenyl)sulfamoyl)-1,4-dihydroquinoline-3-carboxylate 
• 1449221-73-1 1,3-diethyl 2-(((4-(N-(3-(trifluoromethyl)phenyl)sulfamoyl)phenyl)amino)methylene)malonate 

Relevant academic research and scientific papers

4-Oxo-1,4-dihydro-quinoline-3-carboxamides as BACE-1 inhibitors: Synthesis, biological evaluation and docking studies

In this work, we report a series of new 4-oxo-1,4-dihydro-quinoline-3- carboxamide derivatives as β-secretase (BACE-1) inhibitors. Supported by docking study, a small library of derivatives were designed, synthesized and biologically evaluated in vitro. The studies revealed that the most potent analog 14e (IC50 = 1.89 μM) with low cellular cytotoxicity and high predicted blood brain barrier permeability, could serve as a good structure for further modification.

Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains

BRD4, characterized by two acetyl-lysine binding bromodomains and an extra-terminal (ET) domain, is a key chromatin organizer that directs gene activation in chromatin through transcription factor recruitment, enhancer assembly, and pause release of the RNA polymerase II complex for transcription elongation. BRD4 has been recently validated as a new epigenetic drug target for cancer and inflammation. Our current knowledge of the functional differences of the two bromodomains of BRD4, however, is limited and is hindered by the lack of selective inhibitors. Here, we report our structure-guided development of diazobenzene-based small-molecule inhibitors for the BRD4 bromodomains that have over 90% sequence identity at the acetyl-lysine binding site. Our lead compound, MS436, through a set of water-mediated interactions, exhibits low nanomolar affinity (estimated Ki of 30-50 nM), with preference for the first bromodomain over the second. We demonstrated that MS436 effectively inhibits BRD4 activity in NF-κB-directed production of nitric oxide and proinflammatory cytokine interleukin-6 in murine macrophages. MS436 represents a new class of bromodomain inhibitors and will facilitate further investigation of the biological functions of the two bromodomains of BRD4 in gene expression.